Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

Archive ouverte

Rafii, H. | Frère, C. | Benzidia, I. | Crichi, B. | Andre, T. | Assenat, E. | Bournet, B. | Carpentier, A. | Connault, J. | Doucet, L. | Durant, C. | Emmerich, J. | Gris, J.C. | Hij, A. | Le Hello, C. | Madelaine, I. | Messas, E. | Ndour, A. | Villiers, S. | Marjanovic, Z. | Ait Abdallah, N. | Yannoutsos, A. | Farge, D.

Edité par CCSD ; Elsevier -

International audience. Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. VTE management and prophylaxis are critical in cancer patients, but effective therapy can be challenging because these patients are at higher risk of VTE recurrence and bleeding under anticoagulant treatment. Numerous published studies report inconsistent implementation of existing evidence-based clinical practice guidelines (CPG), including underutilization of thromboprophylaxis, and wide variability in clinical practice patterns across different countries and various practitioners. This review aims to summarize the 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and preventing cancer-associated VTE, while minimizing unnecessary or over-treatment. Greater adherence to the 2019 ITAC guidelines could substantially decrease the burden of VTE and improve survival of cancer patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion